Amylyx Pharmaceuticals Inc (AMLX)

$3.78 +0.44 (13.17%)
Market Cap 313.65M
Revenue (ttm) 87.37M
Net Income (ttm) -301.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -345.36%
Debt to Equity Ratio 0.00
Volume 771,100
Avg Vol 787,416
Day's Range N/A - N/A
Shares Out 88.60M
Stochastic %K 71%
Beta -0.51
Analysts Sell
Price Target $7.33

Latest News on AMLX

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 9:00 AM EDT - 14 hours ago

Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Apr 1, 2025, 10:00 AM EDT - 1 day ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

Mar 30, 2025, 10:00 AM EDT - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

Mar 27, 2025, 10:00 AM EDT - 6 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

Mar 25, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 23, 2025, 10:00 AM EDT - 10 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

Mar 20, 2025, 10:00 AM EDT - 13 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

Mar 18, 2025, 10:00 AM EDT - 15 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Mar 13, 2025, 10:00 AM EDT - 20 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Mar 11, 2025, 10:00 AM EDT - 22 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Mar 9, 2025, 10:00 AM EDT - 24 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

Mar 6, 2025, 10:00 AM EST - 27 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 12:02 PM EST - 4 weeks ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2024 Earnings Call Transcript

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

Mar 4, 2025, 10:00 AM EST - 4 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 4, 2025, 6:00 AM EST - 4 weeks ago

Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 9:00 AM EST - 5 weeks ago

Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Feb 24, 2025, 9:00 AM EST - 5 weeks ago

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Feb 11, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 10, 2025, 9:00 AM EST - 7 weeks ago

Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 2, 2025, 10:00 AM EST - 2 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Jan 21, 2025, 9:00 AM EST - 2 months ago

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 13, 2025, 10:00 AM EST - 2 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Jan 10, 2025, 8:26 AM EST - 2 months ago

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Jan 9, 2025, 7:30 PM EST - 2 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Jan 6, 2025, 9:00 AM EST - 3 months ago

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Dec 4, 2024, 7:30 AM EST - 4 months ago

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 27, 2024, 9:00 AM EST - 4 months ago

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Nov 25, 2024, 2:40 PM EST - 4 months ago

Amylyx: AMX0035 PSP Data In Mid-2025 Is Just One Program Moving Along

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 10:06 AM EST - 5 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2024 Earnings Call Transcript

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 7, 2024, 7:00 AM EST - 5 months ago

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Nov 4, 2024, 9:00 AM EST - 5 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Oct 17, 2024, 9:00 AM EDT - 5 months ago

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Oct 15, 2024, 9:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Oct 3, 2024, 3:06 PM EDT - 6 months ago

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 28, 2024, 8:30 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Aug 12, 2024, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 9:02 AM EDT - 8 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2024 Earnings Call Transcript

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Aug 5, 2024, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

Aug 2, 2024, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome

Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?

Jul 10, 2024, 3:32 PM EDT - 9 months ago

Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday?

Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript

Jul 10, 2024, 2:23 PM EDT - 9 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Avexitide Acquisition Conference Call Transcript

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

Jul 10, 2024, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Jul 9, 2024, 4:01 PM EDT - 9 months ago

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25, 2024, 3:35 PM EDT - 10 months ago

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

Jun 21, 2024, 6:07 PM EDT - 10 months ago

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 4, 2024, 9:00 AM EDT - 10 months ago

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript

May 9, 2024, 10:40 AM EDT - 11 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

May 9, 2024, 7:00 AM EDT - 11 months ago

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results